Parabilis Medicines

2024 was a pivotal year in the evolution of Parabilis Medicines and our mission to deliver extraordinary medicines for patients.         We are now called Parabilis Medicines, and were formerly FogPharma. This new name embodies our vision of shooting for the moon with our aspiration to create transformational medicines, yet grounded in a strong sense of pragmatism and execution. 2024 has been an amazing year for us – progress along every dimension of the company. The top highlights demonstrating our substantial progress include:       • We welcomed many extraordinary colleagues to our team, and we were recognized by the BostInno Fire Awards, Biotech Week Boston Awards, and Scrip Awards for our exciting progress and impact within the biotech ecosystem.         • We advanced FOG-001, our first-in-class β-catenin:TCF inhibitor, in its clinical development. FOG-001 is the first of its kind – a designed alpha-helical peptide that our preclinical studies have shown enters tumor cells and inhibits a protein-protein interface that has been considered undruggable for decades due to lack of any small molecule binding cavity.        • We significantly advanced our discovery pipeline with multiple programs now moving towards Development Candidate nomination.  Each of our programs is unique in the industry, and each targets an intractable protein that is a critical driver of cancer.        • We established an important co-create partnership with ARTBIO to discover and develop HEARTs (Helicon Enabled Alpha Radiotherapies) that are intended to deliver cancer-killing alpha particles via a Helicon-chelated Lead-212.          • We invested deeply in and are continuously evolving our Helicon platform that created FOG-001. This platform now integrates cutting-edge AI and several multiplexed, advanced, and automated experimental technologies.       • Finally, we successfully closed a $145 million Series E financing backed by an industry-leading syndicate of investors.       Thank you to our amazing team, the patients who participated in our trials, and our partners, all of whom have made this year a success -- we look forward to building on this momentum in 2025.      Happy New Year from our team to yours!         #ParabilisMedicines #Helicons #CreatingExtraordinaryMedicines #Biotech #Oncology 

This holiday season, Parabilis served up fun and a little friendly competition at our annual winter outing and holiday celebration, which included a spirited pickleball tournament with 36 teams, new branded swag to ring in the new year, and plenty of opportunities to come together as a team. At Parabilis, we’re not just building transformative medicines—we’re also building a community of innovators who support and inspire one another. Cheers to an incredible team and year of achievements in 2024! #ParabilisMedicines #Biotech #TeamBuilding #TeamOffsite

When it comes to peptide design, the possibilities of our Helicon platform are astronomical—literally.  Imagine if the structural diversity of a peptide with only the 20 natural amino acids were a teaspoon of water. 💧 The potential diversity of our Helicons would equal the water of 10 billion Earths!  🌎🌎🌎🌎 Enabled by AI and advanced simulations, our Helicon platform expands the boundaries of peptide science. By leveraging over a thousand custom amino acids, we unlock diversity more than 20 orders of magnitude beyond natural peptides. This unparalleled flexibility allows us to fine-tune chemical and biological properties to tackle previously undruggable targets. Discover how Parabilis is redefining the possible: https://lnkd.in/eZQ-Fdp8  

Today, we’re welcoming Anandan Palani to the Parabilis leadership team as Vice President, Medicinal Chemistry Synthesis.    With nearly 30 years of biopharma R&D experience, Anandan has deep expertise managing high-performing teams, fostering cross-functional collaborations, and building strategic partnerships. Anandan brings specialized expertise in small molecules and peptides. Over the course of his tenure at Merck he led teams in advancing eight preclinical candidates to the clinic resulting in one approved medicine.     We’re excited for Anandan to be on board and to propel our work of creating extraordinary medicines.    #ParabilisMedicines #Biotech #DrugDiscovery #Oncology  

We’re thrilled to share that Parabilis Medicines has been named the winner in the Late-Stage Biotech category at the 2024 BostInno Fire Awards! 🔥  We’re immensely honored to represent the innovative spark that powers the #Boston-area biotech ecosystem. 2024 has been an incredible year for us, from the growth of our team, progressing our programs forward, our Series E financing and a radiopharmaceutical collaboration to the advances in our data science-enabled platform. We’re looking forward to keeping the innovation sparks lit and developing extraordinary, novel medicines for patients with devastating diseases.  See highlights of the awards ceremony here: https://bit.ly/3Z3FZvY      #CreatingExtraordinaryMedicines #Biotech #BostonBiotech 

The countdown to #JPM25 is on!  Join us at JPM as our chairman, president, and CEO, Mathai Mammen, M.D., Ph.D., takes the stage on Tuesday, Jan. 14 from 9:00-9:25 am PT to share Parabilis Medicines’ vision for the future. He’ll spotlight how our innovations are pushing boundaries and creating extraordinary medicines to tackle the toughest challenges in oncology and beyond.  We will be meeting with investors and potential partners at this event. #ParabilisMedicines #Biotech #JPM #JPM2025 

You’ve seen our new name, Parabilis Medicines, and maybe even checked out our new website: https://parabilismed.com But do you know how to pronounce Parabilis?  Our name, a fusion of the Latin ‘para’ (beyond) and Greek ‘bilis’ (possible), embodies our mission to pursue the extraordinary and tackle the toughest, previously undruggable targets. Check out this video, featuring faces of #TeamParabilis sharing a brief how-to for pronouncing our new moniker.  #ParabilisMedicines #CreatingExtraordinaryMedicines #Biotech #DrugDiscovery 

One special feature that sets Helicons apart from other peptide therapies is their tunability. Helicons have tunable clearance characteristics to achieve short or long plasma and tissue residence times, and tunable exposure to different tissue types.     This makes Helicons well-suited for the creation of #radiopharmaceuticals for treating #cancer. By co-developing Helicon-enabled alpha radioligand therapies (HEARTs) with ARTBIO, we’re harnessing Helicons’ tunable characteristics to enable the targeted delivery of lead-212.    Learn more about how Parabilis is #CreatingExtraordinaryMedicines to tackle previously undruggable targets on our website: https://lnkd.in/eZQ-Fdp8     #ParabilisMedicines #DrugDiscovery #Oncology

We were thrilled to recently welcome Mohammed AlQuraishi from Columbia University to Parabilis for a discussion about the state of the art in computational protein design today. Dr. AlQuraishi is a world expert in systems biology who recently played a central role in the development of OpenFold, an open-source AI model for predicting the 3D structures of proteins from their sequences. Following Dr. AlQuraishi’s seminar we had an engaging roundtable discussion about the leading edge of #bioAI modeling, such as prediction of complexes and mutant variants, as well as the current and future role of these models in Parabilis’s target identification and #drugdiscovery. Thank you Dr. AlQuraishi for your time, and for supporting Parabilis’s work of creating extraordinary medicines.  #Biotech #AI #ProteinDesign 

It was such a delight to be invited to participate in this year’s Molecular Machine Learning Conference (#MoML2024) organized by MIT Jameel Clinic. The event brought together a group of innovators at the forefront of applying #AI, machine learning and physics-based modeling to discover new drugs and solve challenging problems in health and medicine.     CEO Mathai Mammen, M.D., Ph.D. presented about how we at Parabilis are breaking new ground in applying AI and data science to discover and develop Helicon therapeutics. Alongside Mathai, #TeamParabilis Donovan Chin, Varun Shivashankar and Fai Khalif enjoyed connecting with attendees from across biotech and academia.     Thank you, Regina Barzilay and Tommi Jaakkola, for organizing such an important gathering to collectively press forward our community’s ability to create breakthrough innovations.     #MachineLearning #Biotech #DrugDiscovery